Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including...
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced...
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments PR Newswire NEW HAVEN...
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase...
Biohaven Announces Proposed Public Offering of Common Shares PR Newswire NEW HAVEN, Conn., April 17, 2024 NEW...
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of...
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments PR...
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd...
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn., Jan. 2...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.